Naoki Ishibashi, MD

Pharmaceutical Research Division
Osaka, Osaka, Japan

Disclosure(s): SHIONOGI & CO., LTD.: Employee

Presentation(s):

• 514 - The Impact of Xeruborbactam on in vitro Activity of Cefiderocol against a Panel of Acinetobacter baumannii Enriched in Isolates with Reduced Cefiderocol Susceptibility

  Saturday, October 19, 2024
  11:30 AM – 11:43 AM US PT